News & Events

14 November 2022

Have a look at our most recent newsletter

Have a look at our 2nd newsletter - The first research period of A-TANGO has been completed, the report has been submitted to the European Commission (EC), new Masterclasses and interview videos are on YouTube, and we have a new project manager. You can access previous newsletters, flyers, posters, templates, and more on the Downloads page.

10 November 2022

4th SC Meeting on 29 November 2022 (remote)

Save the date - The 4th Steering Committee (SC) Meeting will take place on Tuesday, 29 November 2022, online (via Zoom) from 9 am - 4 pm CET. Check your inbox for details from the project management office. We are very much looking forward to seeing you all soon, if not in person, then at least on-screen! You can register here on the A-TANGO Meetings page.

24 October 2022

Free access to EASL educational tools for A-TANGO trainees

All A-TANGO early-career scientists (ECS) can now benefit from EASL’s extensive educational tools and the Young Investigators (YI) community. EASL campus is currently open access for individuals with a MyEASL account. Soon, some of the content will be restricted to EASL members. Therefore, EASL invites the project’s ECS to create a MyEASL account and request a complimentary membership. Feel free to contact Wouter Kruijs (Association & Community Services Manager at EASL) if you have questions. More info.

OUR VISION

More than 10 million people worldwide suffer from decompensated cirrhosis, often as a result of severe alcoholic hepatitis (sAH) or other chronic liver diseases. In its final stages, decompensated cirrhosis leads to acute-on-chronic liver failure (ACLF), a syndrome characterized by multi-organ failure. Effective treatment of ACLF is an urgent and unmet need. The A-TANGO consortium performs Phase 2 clinical studies of an innovative therapeutic strategy that targets inflammation and improves hepatocyte proliferation. We call this novel combinatorial therapy G-TAK. In addition, A-TANGO strives to identify reliable biomarkers for better patient stratification and an increased survival rate.

Read more

OBJECTIVES

  • Obtain ethical and regulatory approval of the planned clinical studies
  • Ensure safe and regulated supply of the required drugs and placebos
  • European multicenter clinical study to establish the safety, pharmacokinetics, and efficacy of our novel therapeutic strategy
  • Explore the pathophysiological mechanisms and evaluate biomarkers
  • Evaluate our results with respect to clinical outcome, treatment impact, and quality of life
  • Exploit our results by identifying economic benefits for the healthcare system, reimbursement strategies, and potential commercial interest
  • Disseminate the therapeutic potential of our novel treatment strategy to stakeholders and increase awareness of end-stage liver disease

Read more

SCIENTIFIC COORDINATOR

Prof. Dr. Rajiv Jalan (EF CLIF)
Travessera de Gràcia 11, 7th floor
08021 Barcelona
Spain

CLINICAL STUDY SUPERVISOR

Dr. med. Cornelius Engelmann (Charité)
Augustenburger Platz 1
13353 Berlin
Germany

PROJECT
MANAGEMENT

concentris research management gmbh
Ludwigstr. 4
82256 Fürstenfeldbruck
Germany